Stoke Therapeutics (NASDAQ:STOK) Insider Sells $43,815.39 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,461 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider directly owned 40,702 shares of the company’s stock, valued at approximately $1,220,652.98. The trade was a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $203,473.64.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $33.51 on Friday. The stock’s 50 day simple moving average is $32.61 and its 200 day simple moving average is $30.09. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $40.22. The firm has a market cap of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares during the period. Jane Street Group LLC raised its position in shares of Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after purchasing an additional 15,001 shares during the period. Geode Capital Management LLC grew its position in shares of Stoke Therapeutics by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock valued at $11,044,000 after purchasing an additional 70,935 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Stoke Therapeutics by 33.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock valued at $108,000 after purchasing an additional 2,384 shares during the period.

More Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Analysts Set New Price Targets

Several research firms have weighed in on STOK. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC boosted their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.